Companies › Nkarta
1 active drug program in 3 registered trials: 3 Phase 1; Immunology, Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NKX019 CD19-directed CAR NK cell therapy | CD19 | Phase 1 | Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-Hodgkin | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06557265 | NKX019 | Phase 1 | Lupus Nephritis | Immunology | Apr 2027 |
| NCT06733935 | NKX019 | Phase 1 | Systemic Sclerosis | Immunology | Oct 2028 |
| NCT05020678 | NKX019 | Phase 1 | Lymphoma, Non-Hodgkin | Oncology | Dec 2038 |
Cash and short-term investments of $157m on 2026-09-30; operating cash outflow about $105m a year; runway about 18 months at that burn, to Mar 2028
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.